Search

News Prediabetes as a Risk Factor for Overall Mortality and Development of CVD

Prediabetes represents a glucose metabolism disorder with a high risk of developing diabetes. According to the expert panel of the American Diabetes Association (ADA), this risk is up to 70%. A recently published meta-analysis confirms that prediabetes is a significant risk factor for mortality and the development of cardiovascular (CV) diseases not only in the general population but also in patients with known CV disease, and its treatment should therefore be part of cardiovascular prevention.

Source: Modern Treatment of Diabetes 16. 9. 2022

News New Treatment Options for Hemophilia Come with Discussions on Important Issues

The organizing committee of this year's virtual congress of the European Association for Haemophilia and Allied Disorders (EAHAD 2021) promised in the opening speech a "showcase of the latest innovations and advances in the field of hemophilia and bleeding disorders." The program naturally included discussions on current research findings and practical experiences. Topics included the potential role of coagulation factor VIII even with non-factor therapies and the importance of monitoring the success of new therapeutic approaches.

Source: Quality Life Even with Hemophilia 24. 3. 2021

Články časopisu Analysis of the results of radiotherapy and chemoradiotherapy on the background of immunotherapy of patients with cancer of the oral cavity and oropharynx

Author of the article: H. A. Hirna Source: Klinická onkologie | 3/2022 17. 6. 2022

News Treatment of Schizophrenia in a Patient at Risk of Developing Metabolic Syndrome –⁠ Interactive Case Study

A 34-year-old man has been under psychiatric care for 3 years due to a psychotic disorder. Three years ago, he had his first short hospitalization due to marked paranoid symptoms: feelings of being watched, eavesdropping, auditory hallucinations of an imperative nature...

Source: Modern Treatment of Schizophrenia 17. 7. 2023

News Psychotic patient with high cardiometabolic risk –⁠ interactive case report

The following case report describes the treatment of a patient diagnosed with paranoid schizophrenia following a relapse of the disease. During therapy, complications arose in the form of weight gain, deterioration of metabolic parameters, sedation, and sexual dysfunction. Additionally, the patient is not capable of adhering to the principles of a healthy lifestyle. Is it possible to find an optimal treatment approach even in such a case?

Source: Modern Treatment of Schizophrenia 9. 12. 2021

News Familial Hypercholesterolemia and COVID-19: Connections and Risks

Patients with familial hypercholesterolemia (FH) likely have a higher risk of COVID-19 complications both in the acute phase of the infection and for a relatively long period after its occurrence.

Source: Hypercholesterolemia 18. 3. 2021

Články časopisu Hereditary angioedema –⁠ neglected diagnosis

Author of the article: P. Králíčková, E. Burešová, T. Freiberger, I. Tachecí Source: Vnitřní lékařství | 9/2010 7. 9. 2010

News Metamizole in the Treatment of Acute Postoperative Pain

In many countries, metamizole is considered a first-choice non-opioid analgesic. The analysis presented below, published in the Cochrane Database of Systematic Reviews, examined the efficacy and safety of metamizole in the treatment of acute postoperative pain.

Source: Analgesia 25. 5. 2021

Články časopisu Cannabis –⁠ therapy for the future?

Author of the article: Jan Hajer Source: Vnitřní lékařství | 7-8/2015 10. 9. 2015

News Safety and Tolerance of Metamizole in Postoperative Analgesia in Children

Due to the potential serious side effects of metamizole, the use of this drug in children is often a topic of discussion. Therefore, a prospective multicenter observational non-interventional post-marketing safety study aimed to evaluate the safety of using metamizole in children, with an emphasis on hemodynamic, anaphylactic, or respiratory reactions and agranulocytosis.

Source: Analgesia 16. 3. 2020

News Doc. Milan Sova: AAT substitution is available to all indicated patients. It is therefore crucial to now educate about the necessity of regular treatment

Alpha-1-antitrypsin deficiency (AATD) is one of the most common genetic disorders in adults. It is usually associated with the early development of chronic obstructive pulmonary disease (COPD) or liver damage. We discuss how modern substitution therapy can change patients' prognosis and when to consider this diagnosis with the head of the Clinic of Pulmonary Diseases and Tuberculosis at Masaryk University Faculty of Medicine and Brno University Hospital, Doc. MUDr. Milan Sova, Ph.D.

Source: Deficiency of Alpha-1-Antitrypsin 18. 1. 2024

News Efficacy of Baricitinib in Long-term Therapy of Rheumatoid Arthritis

Baricitinib selectively and reversibly inhibits Janus kinases JAK1 and JAK2 and is used in the treatment of adults with active rheumatoid arthritis (RA). Its safety during long-term administration has already been demonstrated by previous analyses, with treatment durations of up to 7 years. Equally important is the long-term efficacy of this drug, which was the focus of work presented in June of this year at the annual European rheumatology congress EULAR 2020.

Source: Biological Treatment 26. 10. 2020

News Characteristics of Patients with Alpha-1 Antitrypsin Deficiency –⁠ Two-Year Data from the EARCO Registry

The international registry of individuals with alpha-1 antitrypsin deficiency (AATD) named EARCO has collected data on 1,044 patients from 15 countries, including the Czech Republic, over its first 2 years of existence. In December 2022, the characteristics of patients enrolled from February 2020 to May 2022 were published. They provide information on the prevalence of AATD genotypes, their clinical phenotypes, factors associated with worsening lung function, and the impact of augmentation therapy.

Source: Deficiency of Alpha-1-Antitrypsin 28. 6. 2023

News Neutropenia with Thrombocytopenia after Alemtuzumab? −⁠ Case Report

Early neutropenia with thrombocytopenia is not a common side effect of alemtuzumab. However, the patient in the following case report by Italian colleagues was affected. What was the outcome?

Source: Multiple Sclerosis 1. 11. 2023

News Lorlatinib showed significant benefit in 1st line treatment of advanced ALK-positive non-small cell lung carcinoma

In the international CROWN study, lorlatinib compared to crizotinib led to a 72% reduction in the risk of disease progression or death and significant improvement in intracranial response to treatment in previously untreated patients with advanced ALK-positive non-small cell lung carcinoma (NSCLC). The results were published in November 2020 in the prestigious New England Journal of Medicine.

Source: Genetic Profile and Treatment of NSCLC 30. 3. 2021